Drugs / LY3164530
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02221882 | Aug 2014 → Mar 2017 | metastatic neoplasm, neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3164530 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02221882 ↗ |
| Route | Intravenous | “Administered IV.” NCT02221882 ↗ |
| Target | EGFR | “Epidermal Growth Factor Receptor (EGFR)” NCT02221882 ↗ |
| Target | MET | “Mesenchymal-Epithelial Transition Factor (MET)” NCT02221882 ↗ |